ResMed Issues First-Ever Revenue Guidance to Calm Investor Nerves
RMD sits 18% above its 52-week low of $180.265.
Summary
ResMed is providing revenue guidance for the first time, a move CEO Michael Farrell says is meant to reassure investors. The announcement comes just hours after the company reported Q4 results with revenue up 8.6% to $1.3 billion and GAAP EPS of $2.64. The debut guidance signals management confidence in visibility and growth trajectory, particularly following the recent MatrixCare divestiture and ongoing patent disputes. No specific guidance figures were disclosed in the headline, but the commitment to forward-looking metrics is a notable shift in disclosure policy. This follows a mixed backdrop: a $490 million asset sale in July, a patent board ruling against the company, and routine insider selling under 10b5-1 plans.
At the time of this announcement, RMD was trading at $212.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32.4B. The 52-week trading range was $180.27 to $293.81. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.